KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Share-based Compensation (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Share-based Compensation for 7 consecutive years, with $17.9 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 14.5% to $17.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.6 million through Dec 2025, down 22.62% year-over-year, with the annual reading at $76.6 million for FY2025, 22.62% down from the prior year.
  • Share-based Compensation hit $17.9 million in Q4 2025 for GoodRx Holdings, down from $18.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $46.5 million in Q1 2021 to a low of $10.2 million in Q3 2022.
  • Historically, Share-based Compensation has averaged $23.5 million across 5 years, with a median of $22.7 million in 2021.
  • Biggest YoY gain for Share-based Compensation was 2514.38% in 2021; the steepest drop was 92.76% in 2021.
  • Year by year, Share-based Compensation stood at $16.8 million in 2021, then soared by 75.08% to $29.4 million in 2022, then dropped by 2.16% to $28.8 million in 2023, then fell by 27.17% to $21.0 million in 2024, then dropped by 14.5% to $17.9 million in 2025.
  • Business Quant data shows Share-based Compensation for GDRX at $17.9 million in Q4 2025, $18.1 million in Q3 2025, and $21.4 million in Q2 2025.